This case describes a 16-year-old woman treated successfully by a bone marrow transplant from her HLAidentical brother for refractory acquired pure red cell aplasia. Conditioning was as for severe aplastic anaemia with cyclophosphamide 4 ؋ 50 mg/kg and antithymocyte globulin. Complete donor type engraftment at 3 months reversed to full autologous reconstitution at 2 years with normal haemopoiesis. The potential implications on pathogenesis of the disease as well as on treatment of autoimmune disorders by stem cell transplantation are discussed. Keywords: acquired pure red cell aplasia; marrow transplantation; autoimmune diseases PRCA is a rare haematological disease characterized by selective marrow erythroid aplasia. The congenital form of this disease is termed Diamond-Blackfan anaemia (DBA).
PRCA is a rare haematological disease characterized by selective marrow erythroid aplasia. The congenital form of this disease is termed Diamond-Blackfan anaemia (DBA). 1 The acquired form can be transient or sustained. Transient PRCA is often associated with a parvovirus B19 infection, 2 but other viral aetiologies are discussed. Patients with acquired PRCA often establish thyomoma and erythropoietin antibodies, thus linking an autoimmune disorder and contributing to its aetiology. [3] [4] [5] [6] [7] Many cases of acquired PRCA may respond to conventional immunosuppressive therapies, but novel therapeutic strategies for refractory acquired PRCA are warranted.
Case report
We report a 16-year-old woman with acquired refractory PRCA treated for the first time by high-dose immunosuppressive therapy followed by allogeneic BMT after she failed to respond to conventional treatment. At diagnosis the haemoglobin was 5.3 g% with 0.4% reticulocytes (norm: 0.8-2.5%), platelets and leucocytes were normal. Physical examination was normal, except for signs of anaeCorrespondence: Dr A Gratwohl, Division of Haematology, Department of Medicine, Kantonsspital, CH-4031 Basel, Switzerland Received 10 November 1998; accepted 6 January 1999 mia. The bone marrow was normocellular and demonstrated a maturation arrest in erythropoiesis, hyperplastic myelopoiesis and normal megakaryopoiesis. In vitro stem cell cultures revealed a maturation arrest in the colony forming unit-erythroid. The patient's serum did not specifically inhibit growth, and inhibition of growth by T-lymphocytes was not tested. 8 Cytogenetic analysis was normal. Serology for parvovirus B19 revealed no evidence of active infection. However, positive IgG and negative IgM serology were suggestive of previous exposure. The patient's erythropoietin level was increased to 206.4 mU/ml (norm: 4-16.4 mU/ml). She received erythrocyte transfusions and steroids for 5 weeks (prednisone 75 mg/day for 6 days, then 50 mg/day for 4 weeks) as first-line therapy. However, treatment with steroids did not reverse the need for continual transfusions. Additional treatment included intravenous immunoglobulins (Sandoglobulin 0.5 g/kg body weight, Swiss Central Laboratory of Red Cross, Berne, Switzerland) for 3 days, 4 and cyclosporin A (CsA) 300 mg/day for 6 months and resulted only in a transient improvement of anaemia. CT scan was suggestive of thymic enlargement and thus a thymectomy was performed. However, after surgery no haematological improvement was observed and histological examination of the thymus revealed normal thymic tissue. According to a case report, a trial with buserelin LHRH-Analoga (Suprefact, Hoechst Marion Roussel) 900 g/day was undertaken. 9 However, the patient remained dependent on erythrocyte transfusions of which she had received a total of 63.
Because of persistent anaemia, bone marrow transplantation was considered to treat the refractory acquired PRCA and alleviate the need for continuous transfusion support and iron chelating therapy. After ethics committee approval and informed consent, the patient underwent allogeneic BMT from her HLA-identical brother. In view of her young age and the relatively low risk of transplant-related mortality, an allogeneic transplant was considered to be the best choice of therapy. Conditioning was with cyclophosphamide 50 mg/kg/day for 4 days and antithymocyte globulin (ATG) 30 mg/kg/day for 3 days consistent with treatment for SAA. A total of 2.6 ϫ 10 8 unmanipulated nucleated cells (CD34 ϩ cells: 2.03 ϫ 10 6 ) were infused. CsA was given to prevent GVHD. The patient developed generalized erythema and hyperbilirubinaemia with some ascites, which were interpreted as acute GVHD II with additional manifes-tations of transient veno-occlusive disease. After an aplastic period of 19 days, she showed full haematological reconstitution. Cytogenetic studies of the bone marrow at 3 months revealed a male karyotype (donor), and at 6 months a female karyotype (recipient), confirmed by DNA polymorphism studies. At 12 months, cytogenetic analysis revealed a chimeric bone marrow karyotype. Of 29 metaphases examined, 10 showed a male and 19 a female karyotype. The 2-year cytogenetic analysis again showed reversal to a 100% female karyotype, again confirmed by DNA polymorphism studies. CsA was stopped 10 months after BMT (CsA 200 mg/day was given until 9 months after BMT and after that 100 mg/day). The patient remains in CR with normal autologous haematopoiesis. Three years after the BMT she is healthy, doing well and working full time.
Discussion
Many cases of acquired PRCA may respond to conventional immunosuppressive therapies, but novel therapeutic strategies for refractory acquired PRCA are warranted. 10 This case report shows CR for the first time after allogeneic BMT in a patient with refractory acquired PRCA. The restoration of normal autologous haematopoiesis suggests that PRCA is an autoimmune disease similar to SAA, pure white cell aplasia (PWCA) and certain other bone marrow diseases. Until recently, bone marrow failure was considered secondary to physical or chemical insults, infections or nutritional deficiencies. New considerations suggest that PRCA, SAA, PWCA and certain other bone marrow diseases are induced by immunological mechanisms that can be triggered by an intrinsic stem cell defect or by cell damage after an extrinsic insult. 11 The association of PRCA with thymoma or lymphoma further suggests an autoimmune aetiology. 2, 3, 6, 7, 12, 13 In contrast to SAA, which involves all three lineages, red cells, white cells and platelets, PRCA is limited to the red cell lineage.
Treatment strategies for acquired PRCA include immunosuppressive therapies with steroids, CsA, immunoglobulins, and thymectomy as first-line treatment. 2 They are ill-defined for patients with refractory disease. Corticosteroids are recommended for young adults, and response rates of about 20-47% have been reported. [12] [13] [14] Charles et al 13 prospectively followed 37 patients with acquired PRCA. Of 21 patients, 17 received prednisone alone as their initial treatment, and eight (47%) entered complete remission. Overall response rates (CR and PR) to CY, ATG and CsA were 40% (six of 15), 62% (eight of 13) and 67% (two of three) respectively. To date, BMT has been used for congenital PRCA (Diamond-Blackfan anaemia (DBA)), but not for acquired PRCA. Mugishama et al 15 reported 10 children with DBA who received BMT from an HLA-identical sibling (n ϭ 8), maternal (n ϭ 1) or unrelated (n ϭ 1) donor. Among eight recipients of HLA-identical sibling transplants, six were in CR 5-87 months after BMT (2-year probability of survival was 72%). The two recipients of non-HLA-identical sibling transplants died Ͻ2 weeks after BMT. The optimum time for a BMT in DBA is probably after the patient becomes refractory to corticosteroids but before excessive transfusion has been necessary.
The observation in our patient of autologous reconstitution after allogeneic BMT is not unique. Complete remissions of severe aplastic anaemia after conditioning with cyclophosphamide and rejection of the allogeneic graft were described more than 20 years ago. 16 They form the basis of current approaches in the treatment of aplastic anaemia and other autoimmune disease states with high-dose cyclophosphamide alone. 17, 18 The role of the allogeneic graft in this situation of autologous reconstitution and the potential mechanisms of microchimeric status remain open to discussion. 19 The successful treatment of our patient gives strong support to the concept that acquired PRCA is also an autoimmune disease. This case adds to the growing number of patients with serious autoimmune diseases who are being treated and recorded under a combined European Group for Bone and Marrow Transplantation (EBMT/EULAR guidelines). 20 It further suggests that autoimmune diseases can be modified by intensive immunoablation.
In summary, high-dose immunosuppressive therapy with allogeneic BMT should be considered for patients with refractory acquired PRCA with an HLA-identical donor. Our case demonstrates that acquired PRCA can be cured by this approach. The resulting complete restoration of recipient haematopoiesis suggests that autologous and allogeneic BMT should be investigated as a treatment for the rare patients with acquired PRCA.
